The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Disovery Of New Airway Epithelial Genes Regulating Allergic Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$446,934.00
Summary
Asthma is an inflammatory disease of the lungs that affects over 10% of all Australians. A number of drugs are currently available for the treatment of asthma, but there are many people whose asthma does not respond well to treatment. We have identified 2 genes, aP2 and mal1, that may be important in the development of asthma. Drugs targeted against these genes may be useful in the treatment of asthma. In this project, we aim to understand how aP2 and mal1 contribute to disease development.
Investigatin The Causes Of Failed Efferocytosis In COPD-emphysema With A View To Identifying Novel Theraputic Targets
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
COPD is a leading cause of death. Smoking is the major cause of COPD and many sufferers are left with permanent damage and need ongoing treatment even after smoking cessation. Current treatments for COPD generally have limited efficacy. The project will identify the reason for the large number of dying cells and defective clearance of these cells that we have identified in the airways in COPD and study novel treatments that we hope will improve the health and well being of those with COPD.
Structural And Mechanical Determinants Of Airway Hyperresponsiveness
Funder
National Health and Medical Research Council
Funding Amount
$415,219.00
Summary
In asthma and chronic obstructive pulmonary disease, the capacity for airway passages to narrow is increased which limits airflow in and out of the lung and contributes to disease severity. The aim of this project is to identify the underlying physiological abnormalities producing the increased narrowing capacity. The investigations will focus on the role of the airway smooth muscle and epithelial layers that are widely implicated in driving the increased narrowing response, but for which the ev ....In asthma and chronic obstructive pulmonary disease, the capacity for airway passages to narrow is increased which limits airflow in and out of the lung and contributes to disease severity. The aim of this project is to identify the underlying physiological abnormalities producing the increased narrowing capacity. The investigations will focus on the role of the airway smooth muscle and epithelial layers that are widely implicated in driving the increased narrowing response, but for which the evidence remains circumstantial.Read moreRead less
Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specificall ....Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specifically treat fibrosisRead moreRead less
Epidemiology Of Allergic Diseases And The Role Of Early Life Eczema
Funder
National Health and Medical Research Council
Funding Amount
$416,306.00
Summary
Eczema prevents our children from getting a healthy start to life, increases their risk of developing asthma and hay-fever, and we don’t know how to prevent this condition. Dr. Lowe will help identify causes and the outcomes of eczema and allergic diseases in early life, by using a number of important research projects. This research includes an intervention trial that aims to prevent the development of allergic disease and sensitisation, which Dr Lowe leads
The Role Of Sedatives And Arousal In Obstructive Sleep Apnoea – Pathophysiology And Therapeutic Utility
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
Recent studies indicate that certain sleeping pills (sedatives) may actually reduce obstructive sleep apnoea (OSA) severity in some patients. This research aims to determine the: 1) characteristics of patients who are most likely to respond to this novel approach. 2) effects of commonly prescribed sedatives on upper airway function and breathing during sleep. 3) utility for a sedative to yield sustained reductions in OSA severity and daytime sleepiness in the appropriately selected OSA patients.
Ontogeny Of Toll (TLR) Function In Normal And Allergic Children: The Impact Of Microbial-rich Environments
Funder
National Health and Medical Research Council
Funding Amount
$387,489.00
Summary
Reduced exposure to bacteria during early life has become a leading candidate to explain the escalating rate of allergic disease. Despite this, the development and maturation of the pathways involved in normal recognition of bacteria in children has not been explored. In this proposal we set out to address this critical shortcoming in both normal and allergic children. Mapping normal maturation of such pathways will help us to identify better early markers of allergic disease.
Understanding The Mechanisms Underlying Airway Remodelling
Funder
National Health and Medical Research Council
Funding Amount
$451,716.00
Summary
Changes in the structure of the lung contribute to the development of disease, but are not responsive to our current therapies. I have found two key structural proteins that are altered in asthma. This research will characterise the regulation and role of these proteins in the disease process. In addition, it will determine if these proteins also contribute to the development of other serious fibrotic diseases, for which there are no current treatments.